Press release
One of Scotland’s most significant scientific success stories in recent times has been celebrated at a special event hosted by the University of Dundee.
Press release
One of Scotland’s most significant scientific success stories in recent times has been celebrated at a special event hosted by the University of Dundee.
Press release
World-leading expertise from the University of Dundee’s Centre for Targeted Protein Degradation (CeTPD) will contribute to a new, global effort to tackle some of the most significant challenges posed by cancer.
Press release
A breakthrough class of molecular glue identified at the University of Dundee could pave the way for a new generation of drugs to target cancers and neurodegenerative diseases.
Press release
Breakthrough research at the University of Dundee may lead to treatments that make two deadly parasitic infections a thing of the past.
Press release
A successful collaboration between the University of Dundee and pharmaceutical company Eisai Co Ltd aiming to create innovative new cancer drugs has been extended for a further three years.
Press release
An international collaboration, featuring scientists from the University of Dundee, has made a breakthrough they hope will help futureproof a revolutionary new field of drug discovery by preventing resistance in cancer therapy.
Press release
Scientists have designed a novel molecule capable of destroying an as-yet undruggable cancer-causing protein – and are making it available for researchers around the world to use in their own work, free of charge
Press release
Researchers from the University of Dundee have discovered a small molecule that helps to eliminate a Parkinson’s disease-causing protein
Impact case study
Bringing about step-change in the diagnosis and treatment of neglected tropical diseases.
News
Amphista Therapeutics, the spin out company from the lab of Professor Alessio Ciulli, was awarded the ‘Financing Deal of the Year’ award 2021 at the Scrip Awards last month. This was in recognition of their $53M Series B funding.